Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2337850
Max Phase: Preclinical
Molecular Formula: C37H39N5O6
Molecular Weight: 649.75
Molecule Type: Small molecule
Associated Items:
ID: ALA2337850
Max Phase: Preclinical
Molecular Formula: C37H39N5O6
Molecular Weight: 649.75
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C[C@H](NC(=O)[C@@H](N)Cc1ccc(OCc2ccccc2)cc1)C(=O)N[C@@H](C[C@]1(O)C(=O)Nc2ccccc21)C(=O)NCc1ccccc1
Standard InChI: InChI=1S/C37H39N5O6/c1-24(40-34(44)30(38)20-25-16-18-28(19-17-25)48-23-27-12-6-3-7-13-27)33(43)41-32(35(45)39-22-26-10-4-2-5-11-26)21-37(47)29-14-8-9-15-31(29)42-36(37)46/h2-19,24,30,32,47H,20-23,38H2,1H3,(H,39,45)(H,40,44)(H,41,43)(H,42,46)/t24-,30-,32-,37+/m0/s1
Standard InChI Key: PNAOQGBEWNBVLZ-NTFIELQZSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 649.75 | Molecular Weight (Monoisotopic): 649.2900 | AlogP: 2.67 | #Rotatable Bonds: 14 |
Polar Surface Area: 171.88 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 6 |
#RO5 Violations: 2 | HBA (Lipinski): 11 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.45 | CX Basic pKa: 7.73 | CX LogP: 2.68 | CX LogD: 2.18 |
Aromatic Rings: 4 | Heavy Atoms: 48 | QED Weighted: 0.12 | Np Likeness Score: -0.06 |
1. Desvergne A, Genin E, Maréchal X, Gallastegui N, Dufau L, Richy N, Groll M, Vidal J, Reboud-Ravaux M.. (2013) Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent noncovalent inhibitors of the eukaryotic 20S proteasome., 56 (8): [PMID:23540790] [10.1021/jm4002007] |
2. Richy N, Sarraf D, Maréchal X, Janmamode N, Le Guével R, Genin E, Reboud-Ravaux M, Vidal J.. (2018) Structure-based design of human immuno- and constitutive proteasomes inhibitors., 145 [PMID:29339252] [10.1016/j.ejmech.2018.01.013] |
Source(1):